These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10897159)

  • 1. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group.
    Cramer JA; Arrigo C; Van Hammée G; Gauer LJ; Cereghino JJ
    Epilepsia; 2000 Jul; 41(7):868-74. PubMed ID: 10897159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam.
    Cramer JA; Arrigo C; Van Hammée G; Bromfield EB
    Epilepsy Res; 2000 Aug; 41(1):29-38. PubMed ID: 10924866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.
    Ben-Menachem E; Falter U
    Epilepsia; 2000 Oct; 41(10):1276-83. PubMed ID: 11051122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
    Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
    Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy.
    Chaisewikul R; Privitera MD; Hutton JL; Marson AG
    Cochrane Database Syst Rev; 2001; (1):CD001901. PubMed ID: 11279737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study.
    Tsai JJ; Yen DJ; Hsih MS; Chen SS; Hiersemenzel R; Edrich P; Lai CW
    Epilepsia; 2006 Jan; 47(1):72-81. PubMed ID: 16417534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.
    Shorvon SD; Löwenthal A; Janz D; Bielen E; Loiseau P
    Epilepsia; 2000 Sep; 41(9):1179-86. PubMed ID: 10999557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
    Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
    Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
    Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
    Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures.
    Zhou B; Zhang Q; Tian L; Xiao J; Stefan H; Zhou D
    Epilepsy Behav; 2008 Feb; 12(2):305-10. PubMed ID: 18024209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.
    Glauser TA; Pellock JM; Bebin EM; Fountain NB; Ritter FJ; Jensen CM; Shields WD
    Epilepsia; 2002 May; 43(5):518-24. PubMed ID: 12027913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
    Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
    Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
    Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid onset of action of levetiracetam in refractory epilepsy patients.
    French J; Arrigo C
    Epilepsia; 2005 Feb; 46(2):324-6. PubMed ID: 15679515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam.
    Kinirons P; McCarthy M; Doherty CP; Delanty N
    Seizure; 2006 Sep; 15(6):387-92. PubMed ID: 16766211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
    Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
    Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
    Stefan H; Wang-Tilz Y; Pauli E; Dennhöfer S; Genow A; Kerling F; Lorber B; Fraunberger B; Halboni P; Koebnick C; Gefeller O; Tilz C
    Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
    Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B;
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam.
    Cramer JA; Van Hammée G;
    Epilepsy Behav; 2003 Apr; 4(2):118-23. PubMed ID: 12697135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review.
    Perry MS; Benatar M
    Epilepsia; 2007 Jun; 48(6):1123-7. PubMed ID: 17430408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.